Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538043 | 0.86 | HTR7 (0.47) | LMNAKDM4EHTTHTR7MAPT | |
| SCHEMBL34475296 | 0.86 | HTR7 (0.47) | LMNAKDM4EHTTHTR7MAPT | |
| SCHEMBL2131582 | 0.82 | KDM4E (0.33) | LMNAKDM4EHTTHTR7MAPT | |
| SCHEMBL29233757 | 0.78 | ALOX5AP (0.39) | MAPK1SMN1; SMN2ALOX5APFEN1RAB9A | |
| SCHEMBL31437246 | 0.77 | S1PR4 (0.44) | LMNAKDM4EHTTMAPTMAPK1 | |
| SCHEMBL8710247 | 0.77 | S1PR4 (0.44) | LMNAKDM4EHTTMAPTMAPK1 | |
| SCHEMBL27321675 | 0.77 | MAPT (0.50) | LMNAKDM4EHTTHTR7MAPT | |
| SCHEMBL5248896 | 0.75 | L3MBTL1 (0.32) | LMNAKDM4EMAPTMAPK1CYP1A2 | |
| SCHEMBL17919290 | 0.75 | PTPN1 (0.45) | LMNAKDM4EHTR7MAPTMAPK1 | |
| SCHEMBL29744608 | 0.75 | ALOX5AP (0.42) | LMNAKDM4EHTTHTR7ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| EP-4219487-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4219487-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | PFIZER INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-3806955-B9 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4219487-A1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3806955-B1 | GLP-1 RECEPTOR AGONISTS AND USES THEREOF | PFIZER (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220387402-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-3972596-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | Pfizer Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340544-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | LMNA 3858/4885KDM4E 1142/4885HTT 2727/4885 |
| US-20220387402-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | GLP1R, GCKR, GCGR | LMNA 4590/4885KDM4E 1262/4885HTT 2682/4885 |
| US-20240059679-A1 | GLP-1 Receptor Agonists and Uses Thereof | GLP1R, GIPR, GCGR | LMNA 3858/4885KDM4E 1142/4885HTT 2727/4885 |
| US-12378230-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | LMNA 3858/4885KDM4E 1142/4885HTT 2727/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | LMNA 4424/4885KDM4E 899/4885HTT 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.